BioXcel Therapeutics (BTAI) Total Liabilities (2017 - 2026)

BioXcel Therapeutics' Total Liabilities history runs 10 years deep, the most recent figure standing at $139.6 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 8.41% year-over-year to $139.6 million; the TTM figure through Mar 2026 stood at $139.6 million (up 8.41% YoY), while the FY2025 annual figure was $140.4 million, up 6.8% from the prior year.
• Total Liabilities was $139.6 million for Q1 2026 at BioXcel Therapeutics, down from $140.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $154.7 million in Q1 2024 to a low of $17.0 million in Q1 2022.
• Historically, Total Liabilities has averaged $124.5 million across 5 years, with a median of $133.5 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 646.91% in 2022, then retreated 16.77% in 2025.
• A 5-year view of Total Liabilities shows it stood at $129.1 million in 2022, then gained by 0.88% to $130.2 million in 2023, then advanced by 0.94% to $131.4 million in 2024, then gained by 6.8% to $140.4 million in 2025, then declined by 0.58% to $139.6 million in 2026.
• The last three Total Liabilities figures came in at $139.6 million (Q1 2026), $140.4 million (Q4 2025), and $133.7 million (Q3 2025), per Business Quant data.